IGM Biosciences Announces Third Quarter 2024 Financial Results …
6 days ago · In This Article: IGMS. – Imvotamab (CD20 x CD3) trials in rheumatoid arthritis, systemic lupus erythematosus and myositis ongoing; initial clinical data expected by mid-2025 …
IGM Biosciences Announces Third Quarter 2024 Financial Results …
About IGM Biosciences, Inc. IGM Biosciences is a clinical-stage biotechnology company committed to developing and delivering a new class of medicines to treat patients with …
IGM Biosciences Announces Third Quarter 2024 Financial Results …
6 days ago · About IGM Biosciences, Inc. IGM Biosciences is a clinical-stage biotechnology company committed to developing and delivering a new class of medicines to treat patients …
Cautious Outlook for IGM Biosciences Amid Delayed Data and …
5 days ago · IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update GlobeNewswire 1d IGM Biosciences GAAP EPS of -$1.01 misses by $0.19, …
IGM Biosciences Announces Third Quarter 2024 Financial Results …
Sep 30, 2024 · IGM Biosciences is a clinical-stage biotechnology company committed to developing and delivering a new class of medicines to treat patients with autoimmune and …
News - IGM Biosciences
Aug 14, 2024 · News. MOUNTAIN VIEW, Calif. , Nov. 04, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and …
IGM Biosciences' New Found Focus: Pivots From Cancer To …
Oct 1, 2024 · On Tuesday, IGM Biosciences Inc. (NASDAQ:IGMS) announced a strategic pivot and pipeline transformation to accelerate and deepen its leadership in developing T cell …
IGM Biosciences Announces Strategic Pivot to Focus Exclusively …
Sep 30, 2024 · IGMS. – Company to prioritize its pipeline of T cell engagers in autoimmune diseases, including ongoing clinical development of imvotamab in rheumatoid arthritis and …
IGM Biosciences Announces Update on IGM-8444 Phase 1 Trial …
Jan 9, 2023 · IGM Biosciences Announces Update on IGM-8444 Phase 1 Trial and Future Clinical Development. – Initial Data from Phase 1 combination with FOLFIRI shows promising activity …
Home - IGM Biosciences
6 days ago · Make an impact at IGM. Help us bring a new class of antibody medicines to patients. » LEARN MORE ABOUT BEING PART OF THE IGM TEAM. Recent News. November 8, …
- Some results have been removed